Skip to Main content Skip to Navigation
Journal articles

Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives

Abstract : Adrenocortical carcinoma is a rare malignant tumor of poor prognosis, frequently requiring additional treatments after initial surgery. Due to its adrenolytic action, mitotane has become the first-line medical treatment in patients with aggressive adrenocortical carcinoma. Over the last 2 years, apart from the classical chemotherapy based on etoposide and platinum salts, several studies reported the use of drugs such as temozolomide, tyrosine kinase inhibitors or immunotherapy, with more or less convincing results. The aim of this review is to give further insights in the use of these drugs, and to describe potential therapeutic perspectives based on recent pangenomic studies, for the future management of these still difficult to treat tumors.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03225545
Contributor : Valérie Gall <>
Submitted on : Wednesday, May 12, 2021 - 4:32:18 PM
Last modification on : Wednesday, May 26, 2021 - 7:56:03 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2022-02-01

Please log in to resquest access to the document

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Collections

Citation

Vincent Amodru, Marie-Eve Garcia, Rossella Libe, Thierry Brue, Yves Reznik, et al.. Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives. Annales d'Endocrinologie, Elsevier Masson, 2021, 82 (1), pp.52-58. ⟨10.1016/j.ando.2020.12.003⟩. ⟨hal-03225545⟩

Share

Metrics

Record views

48